Wealth Enhancement Advisory Services
XLRN

Wealth Enhancement Advisory Services’s Acceleron Pharma XLRN Stock Holding History

Wealth Enhancement Advisory Services’s Portfolio XLRN Stock Details XLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-7,610
Closed -$1.05M – 313
2021
Q1 		$1.05M Buy
7,610
+239
+3% +$30.9K 0.02% 194
2020
Q4 		$930K Buy
+7,371
New +$864K 0.02% 176

Other funds holding XLRN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Wealth Enhancement Advisory Services's XLRN Position: Q2 2021 in Review

Wealth Enhancement Advisory Services sold out of Acceleron Pharma (XLRN) in Q2 2021, closing a stake of 7,610 shares — an estimated $1.05M sold.

Wealth Enhancement Advisory Services first reported a position in XLRN in Q4 2020 and held it in 2 quarters. The position peaked at $1.05M in Q1 2021. 271 funds tracked by Wall St. Rank hold XLRN as of Q2 2021.

  • Wealth Enhancement Advisory Services reported no remaining Acceleron Pharma position as of Q2 2021 after selling out during the quarter.
  • Wealth Enhancement Advisory Services sold 7,610 Acceleron Pharma shares in Q2 2021, an estimated $1.05M.
  • Wealth Enhancement Advisory Services first reported a position in Acceleron Pharma in Q4 2020 and held it in 2 quarters.
  • Wealth Enhancement Advisory Services's Acceleron Pharma position peaked at $1.05M in Q1 2021.
  • 271 funds tracked by Wall St. Rank held Acceleron Pharma as of Q2 2021.

Based on Wealth Enhancement Advisory Services's 13F filing for Q2 2021, filed 10 Aug 2021.